Medigene AG Logo

Medigene AG

MDG1 | F

Overview

Corporate Details

ISIN(s):
DE000A40ESG2
LEI:
391200I33JD2DKZGDX06
Country:
Germany
Address:
Lochhamer Straße 11, 82152 Planegg
Sector:
Professional, scientific and technical activities
Industry:
Research and experimental development on natural sciences and engineering

Description

Medigene AG is an immuno-oncology platform company developing T cell receptor (TCR)-guided therapies to treat cancer. Its proprietary End-to-End Platform generates what it terms 3S (sensitive, specific, and safe) T cell receptors for use in multiple therapeutic modalities, including TCR-engineered T cell (TCR-T) therapies, TCR-natural killer cell therapies, and TCR-guided T cell engagers. These technologies are applied to its in-house product pipeline, such as its lead candidate MDG1015, and through partnerships. In August 2025, it was announced that insolvency proceedings were opened for the company's assets.

Social Media

Stop Scraping. Start Analyzing.

You're viewing a fraction of the data available for Medigene AG. Get complete, real-time, and AI-ready data via the API the pros use.

Get Instant API & Bulk Data Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Date Filing Language Size Actions
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2025-04-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2024 bis zum 31.12.2024
German 6.4 KB
2024-10-16 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-09-18 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2024 bis zum 31.12.2024
German 2.2 KB
2024-08-14 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2024 bis zum 30.0…
German 183.1 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-06-28 00:00
Report Publication Announcement
Hinweis auf Halbjahresfinanzbericht vom 01.01.2024 bis zum 30.06.2024
German 6.4 KB
2024-05-06 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 789.0 KB
2024-03-28 00:00
Annual Report
English 9.9 MB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-03-04 00:00
Report Publication Announcement
Hinweis auf Konzernabschluss vom 01.01.2023 bis zum 31.12.2023
German 6.4 KB
2024-02-23 00:00
Regulatory News Service
§§ 264 Abs. 3, 264b HGB zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 2.1 KB
2023-08-17 00:00
Interim Report
Halbjahresfinanzbericht nach WpHG zum Geschäftsjahr vom 01.01.2023 bis zum 30.0…
German 171.2 KB
2023-04-26 00:00
Regulatory News Service
Jahres- und Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 665.8 KB
2022-12-22 00:00
Report Publication Announcement
Hinweis auf Jahresfinanzbericht vom 01.01.2022 bis zum 31.12.2022
German 6.4 KB

Automate Your Workflow. Get a real-time feed of all Medigene AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Medigene AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
THERACRYF PLC Logo
Developing sulforaphane-based therapeutics for oncology and behavioural brain disorders.
United Kingdom TCF
Theranexus Logo
Biopharma developing drug candidates for rare neurological diseases like Batten disease.
France ALTHX
TME Pharma N.V. Logo
Clinical-stage biotech developing TME-targeting therapies for aggressive cancers.
Germany ALTME
Toleranzia AB Logo
Developing immune therapies for rare autoimmune diseases like myasthenia gravis.
Sweden TOL
Transgene Logo
Clinical-stage biotech using viral vectors for cancer vaccines and oncolytic viruses.
France TNG
Tvardi Therapeutics Inc. Logo United States of America TVRD
UCAR Logo
A nonprofit consortium managing atmospheric research and providing resources to the scientific community.
France ALUCR
Hong Kong N/A
Urteste S.A. Logo
Developing non-invasive urine tests for early detection & monitoring of multiple cancers.
Poland URT
VALIRX PLC Logo
Developing early-stage therapeutics & diagnostics for oncology and women's health.
United Kingdom VAL